Literature DB >> 18510434

Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans.

Michael M Swarbrick1, Peter J Havel.   

Abstract

Adiponectin is an adipocyte hormone that links visceral adiposity with insulin resistance and atherosclerosis. It is unique among adipocyte-derived hormones in that its circulating concentrations are inversely proportional to adiposity, and low adiponectin concentrations predict the development of type 2 diabetes and cardiovascular disease. Consequently, in the decade since its discovery, adiponectin has generated immense interest as a potential therapeutic target for the metabolic syndrome and diabetes. This review summarizes current research regarding the regulation of circulating adiponectin concentrations by physiological, pharmacological, and nutritional factors, with an emphasis on human studies. In humans, plasma adiponectin concentrations are influenced by age and gender, and are inversely proportional to visceral adiposity. In vitro studies suggest that adiponectin production may be determined primarily by adipocyte size and insulin sensitivity, with larger, insulin-resistant adipocytes producing less adiponectin. While adiponectin concentrations are unchanged after meal ingestion, they are increased by significant weight loss, such as after bariatric surgery. In addition, adiponectin production is inhibited by a number of hormones, including testosterone, prolactin, glucocorticoids and growth hormone, and by inflammation and oxidative stress in adipose tissue. Smoking decreases, while moderate alcohol consumption increases, circulating adiponectin concentrations. Dietary fatty acid composition in rodents influences adiponectin production via ligand-activated nuclear receptors (PPARs); however, current evidence in humans is equivocal. In addition to PPAR agonists (such as thiazolidinediones and fibrates), a number of pharmacological agents (angiotensin receptor type 1 blockers, ACE inhibitors, and cannabinoid receptor antagonists) used in treatment of the metabolic syndrome also increase adiponectin concentrations in humans.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18510434      PMCID: PMC3190268          DOI: 10.1089/met.2007.0029

Source DB:  PubMed          Journal:  Metab Syndr Relat Disord        ISSN: 1540-4196            Impact factor:   1.894


  220 in total

1.  Weight gain in epileptic patients during treatment with valproic acid: a retrospective study.

Authors:  C L Corman; N M Leung; A H Guberman
Journal:  Can J Neurol Sci       Date:  1997-08       Impact factor: 2.104

2.  Different effects of adiponectin isoforms in human monocytic cells.

Authors:  Markus Neumeier; Johanna Weigert; Andreas Schäffler; Gabriele Wehrwein; Ulf Müller-Ladner; Jürgen Schölmerich; Christian Wrede; Christa Buechler
Journal:  J Leukoc Biol       Date:  2006-01-24       Impact factor: 4.962

3.  The role of adipose cell size and adipose tissue insulin sensitivity in the carbohydrate intolerance of human obesity.

Authors:  L B Salans; J L Knittle; J Hirsch
Journal:  J Clin Invest       Date:  1968-01       Impact factor: 14.808

4.  Serum ghrelin, leptin and adiponectin levels before and after weight loss: comparison of three methods of treatment--a prospective study.

Authors:  Efstathios V Kotidis; George G Koliakos; Vasilios G Baltzopoulos; Konstantinos N Ioannidis; John G Yovos; Spiros T Papavramidis
Journal:  Obes Surg       Date:  2006-11       Impact factor: 4.129

5.  Adiponectin acts in the brain to decrease body weight.

Authors:  Yong Qi; Nobuhiko Takahashi; Stanley M Hileman; Hiralben R Patel; Anders H Berg; Utpal B Pajvani; Philipp E Scherer; Rexford S Ahima
Journal:  Nat Med       Date:  2004-04-11       Impact factor: 53.440

6.  Enhanced adiponectin multimer ratio and skeletal muscle adiponectin receptor expression following exercise training and diet in older insulin-resistant adults.

Authors:  Valerie B O'Leary; Ashley E Jorett; Christine M Marchetti; Frank Gonzalez; Susan A Phillips; Theodore P Ciaraldi; John P Kirwan
Journal:  Am J Physiol Endocrinol Metab       Date:  2007-05-08       Impact factor: 4.310

7.  Activation of nuclear factor-kappaB by high molecular weight and globular adiponectin.

Authors:  Fred Haugen; Christian A Drevon
Journal:  Endocrinology       Date:  2007-08-16       Impact factor: 4.736

8.  Prolactin: a diabetogenic hormone.

Authors:  R Landgraf; M M Landraf-Leurs; A Weissmann; R Hörl; K von Werder; P C Scriba
Journal:  Diabetologia       Date:  1977-04       Impact factor: 10.122

9.  Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase.

Authors:  T Yamauchi; J Kamon; Y Minokoshi; Y Ito; H Waki; S Uchida; S Yamashita; M Noda; S Kita; K Ueki; K Eto; Y Akanuma; P Froguel; F Foufelle; P Ferre; D Carling; S Kimura; R Nagai; B B Kahn; T Kadowaki
Journal:  Nat Med       Date:  2002-10-07       Impact factor: 53.440

10.  Diurnal and ultradian dynamics of serum adiponectin in healthy men: comparison with leptin, circulating soluble leptin receptor, and cortisol patterns.

Authors:  Alina Gavrila; C-K Peng; Jean L Chan; Joseph E Mietus; Ary L Goldberger; Christos S Mantzoros
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

View more
  99 in total

1.  Adiponectin resistance parameter as a marker for high normal blood pres-sure and hypertension in patients with metabolic syndrome.

Authors:  S Stojanovic; M Deljanin-Ilic; S Ilic; M Stefanovic; D Petrovic; V Petrovic; M Stojanovic
Journal:  Hippokratia       Date:  2020 Jan-Mar       Impact factor: 0.471

2.  Kisspeptin-10 inhibits proliferation and regulates lipolysis and lipogenesis processes in 3T3-L1 cells and isolated rat adipocytes.

Authors:  Ewa Pruszyńska-Oszmałek; Paweł A Kołodziejski; Maciej Sassek; Joanna H Sliwowska
Journal:  Endocrine       Date:  2017-02-13       Impact factor: 3.633

3.  A low-fat high-carbohydrate diet reduces plasma total adiponectin concentrations compared to a moderate-fat diet with no impact on biomarkers of systemic inflammation in a randomized controlled feeding study.

Authors:  Xiaoling Song; Mark Kestin; Yvonne Schwarz; Pamela Yang; Xiaojun Hu; Johanna W Lampe; Mario Kratz
Journal:  Eur J Nutr       Date:  2015-02-04       Impact factor: 5.614

Review 4.  Novel therapeutic targets in myeloma bone disease.

Authors:  S L Webb; C M Edwards
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

Review 5.  Could the improvement of obesity-related co-morbidities depend on modified gut hormones secretion?

Authors:  Carmine Finelli; Maria Carmela Padula; Giuseppe Martelli; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2014-11-28       Impact factor: 5.742

6.  Adiponectin May Modify the Risk of Barrett's Esophagus in Patients With Gastroesophageal Reflux Disease.

Authors:  Lucy M Almers; James E Graham; Peter J Havel; Douglas A Corley
Journal:  Clin Gastroenterol Hepatol       Date:  2015-01-26       Impact factor: 11.382

7.  Lean mass predicts asthma better than fat mass among females.

Authors:  A Sood; C Qualls; R Li; M Schuyler; W S Beckett; L J Smith; B Thyagarajan; C E Lewis; D R Jacobs
Journal:  Eur Respir J       Date:  2010-06-04       Impact factor: 16.671

8.  Augmented plasma adiponectin after prolonged fasting during ramadan in men.

Authors:  Sadegh Feizollahzadeh; Javad Rasuli; Sorayya Kheirouri; Mohammad Alizadeh
Journal:  Health Promot Perspect       Date:  2014-07-12

9.  Two-year changes in circulating adiponectin, ectopic fat distribution and body composition in response to weight-loss diets: the POUNDS Lost Trial.

Authors:  W Ma; T Huang; M Wang; Y Zheng; T Wang; Y Heianza; D Sun; S R Smith; G A Bray; F M Sacks; L Qi
Journal:  Int J Obes (Lond)       Date:  2016-07-27       Impact factor: 5.095

10.  Changes in serum adiponectin concentrations in critical illness: a preliminary investigation.

Authors:  Bala Venkatesh; Ingrid Hickman; Janelle Nisbet; Jeremy Cohen; John Prins
Journal:  Crit Care       Date:  2009-07-02       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.